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Abstract
The melioidosis bacterium, Burkholderia pseudomallei, is increasingly being recognised as a pathogen in patients with cystic
fibrosis (CF). We have recently catalogued genome-wide variation of paired, isogenic B. pseudomallei isolates from seven
Australasian CF cases, which were collected between 4 and 55months apart. Here, we extend this investigation by
documenting the transcriptomic changes in B. pseudomallei in five cases. Following growth in an artificial CF sputum
medium, four of the five paired isolates exhibited significant differential gene expression (DE) that affected between 32 and
792 genes. The greatest number of DE events was observed between the strains from patient CF9, consistent with the
hypermutator status of the latter strain, which is deficient in the DNA mismatch repair protein MutS. Two patient isolates
harboured duplications that concomitantly increased expression of the b-lactamase-encoding gene penA, and a 35 kb
deletion in another abolished expression of 29 genes. Convergent expression profiles in the chronically-adapted isolates
identified two significantly downregulated and 17 significantly upregulated loci, including the resistance-nodulation-division
(RND) efflux pump BpeEF–OprC, the quorum-sensing hhqABCDE operon, and a cyanide- and pyocyanin-insensitive
cytochrome bd quinol oxidase. These convergent pathoadaptations lead to increased expression of pathways that may
suppress competing bacterial and fungal pathogens, and that enhance survival in oxygen-restricted environments, the latter
of which may render conventional antibiotics less effective in vivo. Treating chronically adapted B. pseudomallei infections
with antibiotics designed to target anaerobic infections, such as the nitroimidazole class of antibiotics, may significantly
improve pathogen eradication attempts by exploiting this Achilles heel.
DATA SUMMARY
1. Whole-transcriptome sequence data have been deposited
into the National Center for Biotechnology Information
(NCBI) Sequence Read Archive (SRA) under BioProject
accession PRJNA398168 (url – https://www.ncbi.nlm.nih.
gov/bioproject/PRJNA398168).
2. The SRA accession number for the raw transcriptomic
data of MSHR5654 is SRR6031143 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031143).
3. The SRA accession number for the raw transcriptomic
data of MSHR5651 is SRR6031144 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031144).
4. The SRA accession number for the raw transcriptomic
data of MSHR5670 is SRR6031145 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031145).
5. The SRA accession number for the raw transcriptomic
data of MSHR5662 is SRR6031146 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031146).
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6. The SRA accession number for the raw transcriptomic
data of MSHR8437 is SRR6031147 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031147).
7. The SRA accession number for the raw transcriptomic
data of MSHR8436 is SRR6031148 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031148).
8. The SRA accession number for the raw transcriptomic
data of MSHR8440 is SRR6031149 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031149).
9. The SRA accession number for the raw transcriptomic
data of MSHR8438 is SRR6031150 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031150).
10. The SRA accession number for the raw transcriptomic
data of MSHR8442 is SRR6031151 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031151).
11. The SRA accession number for the raw transcriptomic
data of MSHR8441 is SRR6031152 (https://www.ncbi.nlm.
nih.gov/sra/?term=SRR6031152).
INTRODUCTION
The Gram-negative soil-dwelling bacterium Burkholderia
pseudomallei causes melioidosis, an opportunistic tropical
infectious disease of humans and animals that has a high
fatality rate [1]. B. pseudomallei is found in many tropical
and subtropical regions globally, and has been unmasked
in temperate and even arid environments following unusu-
ally wet weather events [2–4]. Infection occurs following
percutaneous inoculation from contaminated soil or water,
inhalation, or ingestion. Melioidosis symptoms vary widely
due to the ability of B. pseudomallei to infect almost any
organ, with pneumonia being the most common presenta-
tion [5, 6]. Individuals most at risk of contracting melioi-
dosis include diabetics, those with hazardous alcohol
consumption and the immunosuppressed. There has been
increasing recognition that people with chronic lung
diseases such as cystic fibrosis (CF) are also at a height-
ened risk [7, 8].
CF is a heritable disorder of the CFTR gene, and defects in
CFTR (cystic fibrosis transmembrane conductance regula-
tor) lead to exaggerated airway inflammation, an imbalance
in salt regulation in the lungs and pancreas, and a chronic
overproduction of thick and sticky mucus in the airways
and digestive system [9]. Impaired immunity and mucus
clearance encourage infection and subsequent persistence
and adaptation of opportunistic bacterial pathogens in the
CF lung, leading to the development of bronchiectasis with
subsequent progressive pulmonary decline, and ultimately,
loss of pulmonary function and death [10].
The most common pathogens of the CF lung are Pseudomo-
nas aeruginosa, Staphylococcus aureus, Haemophilus influ-
enzae, and less commonly, Achromobacter xylosoxidans,
non-tuberculosis mycobacteria, Stenotrophomonas malto-
philia and Burkholderia cepacia complex species [11]. The
most common and best-studied CF pathogen is P. aerugi-
nosa, which can adapt to the CF lung environment via
various mechanisms. Convergent pathoadaptations in
P. aeruginosa include the downregulation or loss of viru-
lence factors and motility-encoding loci, emergence of
hypermutators, enhanced antibiotic resistance and immune
evasion facilitated by a switch to mucoidy and a biofilm-
based lifestyle, and altered expression of other loci
enhancing bacterial metabolism and survival within the
nutrient-poor CF lung environment [10, 12].
Improving life expectancy for those with CF has led to an
increased risk of exposure to B. pseudomallei following
travel to melioidosis-endemic regions. Although uncom-
mon, infection of the CF lung by B. pseudomallei has now
been documented in at least 25 cases worldwide [13]. Due
to low total case numbers, comparatively little is under-
stood about the pathogenic role of B. pseudomallei in CF
pulmonary disease. The most common clinical presenta-
tion is chronic infection (76%), which is associated with
accelerated lung function decline [13]. This prevalence
contrasts with melioidosis in non-CF patients, where
chronic infection occurs in only 11% of cases [6]. To bet-
ter understand B. pseudomallei pathoadaptation in the CF
lung, we recently investigated the genome-wide evolution
of isogenic B. pseudomallei strains isolated from seven
Australasian CF patients, which were collected between 4
IMPACT STATEMENT
The melioidosis bacterium Burkholderia pseudomallei is a
rare but important pathogen in cystic fibrosis (CF).
B. pseudomallei infection of the CF airways commonly
shifts towards a chronic state, where it becomes difficult
to eradicate, leading to accelerated lung decline, respira-
tory failure and death. Understanding pathogen adapta-
tion to the CF airways is essential for identifying targeted
treatment regimens that can successfully slow or halt
disease progression. We have recently catalogued the
genome-wide evolution of B. pseudomallei in the lungs of
seven CF melioidosis patients, which revealed several
important adaptations conferring antibiotic resistance,
virulence factor attenuation and genetic loss. Here, we
extend upon our earlier study by characterising paired B.
pseudomallei transcriptomes from five cases using RNA
sequencing (RNA-seq). Differential gene expression was
identified in four of the five cases, and affected loci
involved in antibiotic resistance, quorum sensing, adap-
tation to microaerobic conditions and inhibition of com-
peting pathogen species. Notably, RNA-seq identified
additional within-host evolution signatures not observ-
able with genomic data. Our results provide evidence for
parallel evolution of B. pseudomallei in the CF lung, a trait
that may be exploited for targeted pathogen eradication
and improved patient outcomes.
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and 55months apart [14]. Hallmarks of these infections
included B. pseudomallei persistence despite multiple erad-
ication attempts, multidrug resistance, mutations in
virulence, metabolism and cell wall components, and the
first-documented case of hypermutation in B. pseudomal-
lei. In all except one case, multiple single-nucleotide poly-
morphism (SNP) and insertion-deletion (indel) mutations
were identified, with a high rate of nonsynonymous muta-
tions, many of which were predicted to affect protein
function [14].
RNA sequencing (RNA-seq) provides a detailed view of the
transcriptional landscape in bacterial isolates grown under
different conditions or niches [15], and is now a well-
established method for examining differential gene expres-
sion (DE) in bacterial pathogens [16]. Here, we performed
RNA-seq on strains from five of the CF cases that we have
recently described [14] to catalogue both within-host and
convergent transcriptional evolution during long-term
B. pseudomallei infection in the CF lung. Paired isolates rep-
resenting the initial and the most recent cultures available
from each patient were compared. B. pseudomallei cultures
were grown in an artificial sputum medium [17, 18] to
mimic the conditions found in the CF lung environment.
METHODS
CF isolates
The B. pseudomallei strains used in this study are summar-
ised in Table 1. The history and genomic analysis of these
cases and strains are detailed elsewhere [14].
Artificial sputum medium
This medium was made as described elsewhere [17, 18],
with modifications detailed here. Antibiotics were not used
to maintain media sterility due to concerns that their
addition would alter expression profiles. Due to the imprac-
ticality of its filtration [19], 1 g porcine stomach mucin
(Sigma-Aldrich) dissolved in 40ml ultrapure water was
autoclaved prior to use. All other solutions were sterilised
using a 0.22 µM vacuum filter, apart from the UV-irradiated
egg yolk emulsion (Oxoid), which was treated aseptically.
A stock solution of diethylenetriaminepentaacetic acid
(Sigma-Aldrich) was made by dissolving 59.5mg into 5ml
very basic water (pH=14). CaCl2 was added at a final con-
centration of 0.22 g l 1 (J. Manos, personal communica-
tion). Final concentrations of the components were: 10 g
mucin l 1, 1.39 g salmon sperm DNA l 1 (Sigma-Aldrich),
5 g NaCl l 1, 2.2 g KCl l 1, 0.22 g CaCl2 l
 1, 5 g casein acid
hydrosylate l 1 (Sigma-Aldrich), 10 g BSA l 1 (Roche
Diagnostics), 0.005% diethylenetriaminepentaacetic acid
and 0.5% egg yolk emulsion. Each batch was tested for ste-
rility prior to use by plating 100 µl onto Luria–Bertani (LB)
agar (Oxoid) and incubating aerobically for 24 h. pH was
tested using an aliquot of the medium to ensure it was
within the desired range (pH ~6.5–7). The medium was
stored at 4

C for no longer than 4 weeks prior to use.
Viability counts
Two sets of viability counts were performed for this study.
The first was conducted to determine the number of c.f.u. at
OD590, which enabled us to standardise the starting number
of cells inoculated into the artificial sputum medium. The
second was conducted to verify the final concentration of
cells across all CF isolates, which enabled us to determine
the number of cells for nucleic acid extraction to ensure that
approximately equal cell amounts were processed for each
pair. The CF isolates were subcultured from glycerol stocks
onto LB agar at 37

C for 24 h. Cells were suspended into
PBS followed by spectrophotometric measurement at OD590
in a WPA CO 8000 cell density meter (Biochrom). Tenfold
dilutions and plating of cultures onto LB agar were carried
out, followed by enumeration at 24 h. Viable counts demon-
strated that all CF isolates exhibited a similar cell density
when normalised to an OD590=1.0 (range 1.310
8 to
4.9108 cells). Based on these counts, the starting amount
of culture for the CF isolates was standardised to 105 c.f.u.
for all subsequent experiments.
Growth curves in artificial sputum medium
To minimize laboratory passage, each culture was again
subcultured from the original glycerol stocks onto LB agar
at 37

C for 24 h, followed by a replication of OD590 meas-
urements as determined previously. Based on the viability
count data, samples were then diluted to 106 c.f.u. ml 1 in
PBS. One hundred microlitres of this suspension (~105
c.f.u.) was used to inoculate 1.9ml sputum medium, which
was aliquoted into 14ml Nunc round-bottom culture tubes
(Thermo Fisher Scientific). Due to biosafety concerns, cells
were grown in closed-capped tubes. The cultures were incu-
bated at 37

C by shaking in an orbital incubator shaker
(model BL8500; Bioline) at 50, 200 or 230 r.p.m. for 44 h.
Growth curves were obtained by measuring OD590 at regu-
lar intervals over this period using un-inoculated sputum
medium as the control blank. Shaking at 50 r.p.m. was ini-
tially performed to mimic the low-oxygen conditions of the
CF lung; however, this speed caused heavy sedimentation of
cells and media components, and biofilm formation at the
aerobic interface, both of which led to a decrease in optical
density values over time and unpredictable, non-uniform
growth. Similarly, shaking at 230 r.p.m. was too vigorous for
the cells, as observed by inconsistent, non-reproducible via-
ble counts. When shaking at 200 r.p.m., highly reproducible
optical density values that correlated with viability counts
were obtained (Fig. S1, available with the online version of
this article), and the medium did not readily sediment. This
speed was therefore used for subsequent experiments,
including for RNA harvest. Viability counts were performed
at the time of harvest to ensure uniformity of cell concentra-
tions across all isolates.
RNA extraction from isolates grown in artificial
sputum medium
The CF strains were grown in duplicate lineages prior to
being pooled for extraction, as detailed above. This step was
carried out to minimise the chance of rare but significant
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laboratory-generated mutation(s) affecting gene expression
in one of the lineages. In addition, two independent extrac-
tions were performed for all isolates, apart from the latter
CF11 strain (MSHR8442), where three RNA extractions
were carried out. Based on the growth curve analysis,
nucleic acids for all cultures were extracted at late log phase
(17 h). At the point of harvest, the OD590 of each replicate
was measured to ensure that consistent cell density had
been obtained prior to combining replicates; final viability
counts were also performed. Due to the highly labile nature
of bacterial mRNA, two 100 µl aliquots for each strain were
immediately placed into 200 µl RNAprotect (Qiagen) and
incubated for 5min to preserve their transcription profiles.
Cells were pelleted by centrifugation at 5000 g for 10min,
and the supernatant discarded. Total RNA was extracted
using the RNeasy Protect bacteria mini kit (Qiagen).
B. pseudomallei cells were lysed following the protocol for
genomic DNA extraction [20], with an extended incubation
time in proteinase K and lysozyme of 1.5 h. Lysates were
loaded onto the RNeasy mini columns and extractions were
carried out according to the manufacturer’s instructions,
including the recommended on-column DNase I digestion.
In our hands, we found this DNase I treatment to be insuffi-
cient for removing all contaminating DNA, so extractions
for RNA-seq were further treated using a TURBO DNA-
free kit (Ambion). For each sample, 35 µl extracted RNA
was incubated with 6 U TURBO DNase at 37

C for 32min.
The remaining RNA was not treated with this second round
of DNase; instead, this sample was used as template for PCR
contamination screening, as described below. All samples
were transferred to clean RNase/DNase-free tubes for
downstream processing.
RNA quality control
To verify the removal of DNA from the total RNA extrac-
tions, two contamination screens were performed. The first
was used to determine the removal of salmon sperm DNA,
and the second was to determine the removal of B. pseudo-
mallei DNA. Both the pre- and post-treated RNA samples
were used to test for contamination, in duplicate, with the
former acting as the positive control. The RNA samples
were diluted 1/10 into molecular-grade H2O (Fisher Bio-
tech) prior to PCR. Identification of residual salmon sperm
DNA was investigated by targeting the mitochondrial 12S
rDNA region of vertebrates [21]. Primers 12 S-6F (5¢-
CAAACTGGGATTAGATACC-3¢) and B-12S-9R (5¢-
AGAACAGGCTCCTCTAG-3¢) were used at a final
concentration of 1 µM in a mix containing 1 PCR buffer
(Qiagen), 1 U HotStarTaq, 0.2mM dNTPs, 1 µl template
and molecular-grade H2O in a 15 µl total reaction volume.
Thermocycling conditions comprised 94

C for
5min, followed by 35 cycles of 94

C for 30 s, 52

C for 30 s
and 72

C for 30 s, and a final extension at 72

C for 2min.
Amplicons were detected by agarose gel electrophoresis.
Real-time PCR was used to detect B. pseudomallei DNA
contamination. The mmsA (methylmalonate-semialdehyde
dehydrogenase) housekeeping gene was targeted using the
primers Bp_266152_3012-F1-flap (5¢-AATAAATCA
TAAACGTGAGGCCGGAGATGT-3¢) and Bp_266152_
3012-R1-flap (5¢-AATAAATCATAAGACCGACATCACG
CACAGC-3¢) in combination with a B. pseudomallei-spe-
cific TaqMan MGB probe, 266152-T_Bp (5¢-VIC-CGGTC
TACACGCATGA-3¢), as previously described [22], with
the following modifications: 0.2 µM probe and 0.4 µM each
primer was used, reactions were carried out in a 5 µl total
reaction volume, and cycling was performed to 50 cycles.
RNA storage, shipment and RNA-seq
For each sample, 20 µl total RNA was added to an RNAsta-
ble tube (Biomatrica), gently mixed with the preservation
agent and left to air-dry in a biosafety cabinet for 48 h. Sam-
ples were shipped at ambient temperature to Macrogen
(Geumcheon-gu, Seoul, Republic of Korea) for RNA-seq.
Table 1. Summary of the genetic mutations and differentially expressed genes between paired, sequential B. pseudomallei isolates obtained from
five CF patients (adapted from [14])
Patient Initial and
final isolate
IDs
Time between
collection
(months)
No. of mutational
events (Chr I, Chr II)
No. of genes affected by
mutations (Chr I, Chr II)
No. of DE genes
(Chr I, Chr II)
No. of DE genes
(downregulated,
upregulated)
CF6 MSHR5651,
MSHR5654
27 24 (14, 10) 29 (14, 15) 229 (69, 160) 229 (124, 105*)
CF8 MSHR8436,
MSHR8437
46 12 (7, 5) 39 (5, 34) 32 (1, 31) 32 (32†, 0)
CF9 MSHR5662,
MSHR5670
55 112 79 (40, 39) 792 (381, 411) 792 (558, 234)
CF10 MSHR8438,
MSHR8440
10 0 0 0 0
CF11 MSHR8441,
MSHR8442
14 15 38 (10, 28) 169 (62, 107) 169 (68‡, 101)
*Seven of these genes are upregulated due to a 30 duplication affecting these loci in MSHR5654.
†Twenty-nine of these genes are downregulated due to a 35 kb deletion affecting these loci in MSHR8437.
‡Twenty-five of these genes appear as downregulated due to a 10 duplication affecting a 36.7 kb locus in MSHR8441 compared with only a 2
duplication in MSHR8442 [14].
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Ribosomal RNA was removed by treatment with the Ribo-
Zero rRNA removal kit for bacteria (Epicentre), followed by
100 bp paired-end, stranded library construction using the
TruSeq rapid SBS Kit (Illumina). Libraries were sequenced
on either the HiSeq2000 or the HiSeq2500 platform (Illu-
mina). All samples were extracted from two separate experi-
ments to account for biological variation, except for
MSHR8442, which was extracted thrice. Between 36 and
80million reads were generated for each sequence, corre-
sponding to between 3.6 and 8.1 billion bp each.
RNA-seq analysis
Illumina read filtering was first performed with Trimmo-
matic v0.33 using the following parameters: TruSeq2-PE
adapter removal, leading=3, trailing=3, sliding window=4 :
15 and minimum length=36. Reads were mapped to the
prototypic B. pseudomallei K96243 reference genome
(RefSeq IDs NC_006350 and NC_006351 for chromosomes
1 and 2, respectively [23]) using Bowtie 2 v2.2.1 [24]. For
within-patient analyses, the initial patient genomes were
downloaded from the National Center for Biotechnology
Information (GenBank references JYBG00000000,
JYBH00000000, JYBI00000000, JYBJ00000000 and
JYBK00000000 for MSHR5651 [CF6], MSHR8436 [CF8],
MSHR5662 [CF9], MSHR8438 [CF10] and MSHR8441
[CF11], respectively) and annotated using Prokka v1.12 [25]
with the K96243 proteins as priority (using the
‘  proteins’ flag) prior to Bowtie 2 v2.3.4 analysis. Tran-
script quantification was performed with HTSeq (v0.6.1p1)
[26] using the intersection non-empty mode and
  stranded=reverse parameters. DE analysis was carried
out using the glmFit function of edgeR v3.18.1 [27], imple-
mented in the online Degust 3.1.0 tool (http://degust.erc.
monash.edu/). DE loci were visualised using the ‘volcano
plot’ function within Degust. Several different groups were
compared to determine DE. The first analyses compared
initial and latter isolates within CF patients (Table 1) with-
out summing technical replicates (i.e. the RNA-seq data
from each independent experiment of a single strain) to
identify DE within each patient. To determine convergent
DE loci, we summed the reads for each technical replicate
prior to analysis and then compared all initial versus all lat-
ter isolates, with the latter CF10 isolate excluded due to a
lack of DE in this strain and the initial CF11 isolate
excluded due to >3 years of infection prior to its isolation
[14]. For all analyses, significant DE was defined as a log2
fold change of 1.5 and a false discovery rate of 0.01. To
improve visualisation of DE loci in the volcano plot of the
initial and latter comparison (Fig. 1), highly expressed DE
loci in only a single strain were omitted.
RESULTS
DE among CF isogenic pairs
DE was observed in four of the five CF pairs, with only
CF10 failing to yield significant transcriptional differences
(Fig. 1). We have previously shown that no genetic variants
separate the CF10 strains, which had the shortest time
between collection of only 10months [14]. This lack of sig-
nificant transcriptional differences rules out epigenetic
effects (e.g. DNA methylation) on gene expression between
the CF10 isolates, at least under the tested growth condi-
tions, and illustrates that RNA-seq is a robust methodology
that is not readily prone to false-positive results.
Of the four pairs with significant DE, CF8 had the fewest
with 32 loci, followed by CF11, CF6 and CF9 with 169, 229
and 792 DE loci, respectively (Fig. 1, Table 1). These paired
isolates were collected 46, 14, 27 and 55months apart,
respectively. There was good correlation between the pro-
portion of DE loci and the genome-wide mutations cata-
logued between these pairs [14], with 12, 15, 24 and 112
mutational events (i.e. SNPs, indels, deletions or gene dupli-
cations) identified in CF8, CF11, CF6 and CF9, respectively
(Table 1). The elevated number of mutations seen in CF9 is
due to a mutS mutation in the latter strain, which confers a
hypermutator phenotype, the first time hypermutation has
been described in B. pseudomallei [14]; this in turn contrib-
utes to a high number of DE genes. However, when compar-
ing the ratio of DE genes to mutational events, CF11 had
the highest proportion of DE genes (11.3), followed by CF6
(9.5), CF9 (7.1) and CF8 (2.7). There was a significant skew
towards DE genes located on chromosome II, which con-
tains a lower proportion of housekeeping genes than chro-
mosome I [23]. Despite encoding only 44% of the genome
by size and 41% of coding sequences, chromosome II loci
were significantly overrepresented in the non-hypermutator
CF pairs (Pearson’s 2 test P<0.001), with between 63 and
97% of the DE genes residing on chromosome II. In CF9,
there was a non-significant trend towards chromosome II
loci, with 52% of DE loci located on this chromosome,
pointing to the more random nature of mutations in the
hypermutator compared with the other cases (Table S1). In
addition, to detect any significant DE in the pangenome, we
performed DE analysis using the initial strain from each
patient as a reference and compared these results with those
obtained using K92643 (Tables S1 and S2). On balance, the
within-patient analyses were almost identical to those using
the K96243 reference, with most discrepancies attributable
to differences in gene annotation methods.
Many DE genes are absent in the strain found in
chronic-carriage melioidosis patient 314 (P314)
We compared the DE loci in the CF strains to those genes
mutated in the strain found in chronic-carriage melioidosis
case P314. P314 has the longest B. pseudomallei infection
ever documented, and despite multiple eradication
attempts, continues to harbour this bacterium in the airways
since first being diagnosed in 2000. We have previously
shown that the genome of a 139month isolate from P314,
MSHR6686, shows dramatic adaptation to the lung envi-
ronment, including the loss of 285 kb of chromosome II at
four separate locations that collectively encompass 221
genes [28]. When compared with genes lost in MSHR6686,
there was a 9, 15, 20 and 97% overlap in the latter isolates
from CF9, CF6, CF11 and CF8, respectively (Table S1). The
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proportion of downregulated genes varied across this data-
set, ranging from 13% for CF11 to 100% for CF8, demon-
strating that the effect on gene expression at these loci is not
unidirectional, with certain overlap loci in fact being upreg-
ulated in CF6, CF9 and CF11. Of note, all 29 genes
(BPSS1131–BPSS1159) that were lost due to a large deletion
in the latter CF8 isolate [14] were also absent in MSHR6686
[28], providing further evidence of their dispensability for
long-term B. pseudomallei survival in the mammalian host.
As expected, DE showed dramatic downregulation of
between 8 and 14 log2 fold (341 to 15 886) of these loci
(Table S1).
DE of surface antigens in the CF6, CF9 and CF11
pairs
B. pseudomallei produces four capsular polysaccharides
(CPS-I to -IV) and a lipopolysaccharide (LPS). However,
only CPS-I (encoded by BPSL2786–BPSL2810) and LPS
(encoded by BPSL1936 and BPSL2672–BPSL2688) are
associated with virulence in mammals [29, 30]. Our previ-
ous genomic analysis of the CF pairs identified missense
mutations affecting the LPS loci wzt (BPSL2681) and
rmlA (BPSL2685) in CF6, a missense mutation affecting a
putative LPS biosynthesis gene BPSL1119 in CF11 and a
CPS-I frameshift mutation affecting wcbA (BPSL2809) in
CF11 [14].
Consistent with being under heavy selection during chronic
infection, we observed DE of several surface polysaccharide
loci in the CF6, CF9 and CF11 pairs, the most dramatic of
these being in CF9, with 46 downregulated surface polysac-
charide genes (Table S1). The LPS loci wbiE (BPSL2676)
and wbiD (BPSL2677) were downregulated by ~1.8 fold
(3) in the latter CF9 isolate. In addition, the poorly char-
acterised LPS biosynthesis-related membrane protein loci
BPSS1683–BPSS1685 were downregulated by ~5.9 fold
(60). This isolate also exhibited downregulation of all
CPS-I loci (except wcbC) of between 1.7- and 3.1-fold (3 to
Fig. 1. Degust volcano plots showing differentially expressed (DE) genes between paired B. pseudomallei isolates retrieved from five
CF lungs, and between initial and latter isolates. Four of the five pairs exhibited DE; CF10, with the shortest time between isolates,
exhibited no genetic or significant transcriptomic changes. CF6, CF8, CF9 and CF11 pairs were separated by 229, 32, 792 and 169 DE
loci, respectively. The 32 DE loci in CF8 were all downregulated; DE genes in CF6, CF9 and CF11 were downregulated or upregulated.
Nineteen loci were differentially expressed between initial and latter isolates, of which 17 were upregulated. Blue, genes with no signif-
icant DE; red, genes with significant DE. FDR, false discovery rate; FC, log2 fold change.
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8). In contrast, the latter isolate from CF11 showed upre-
gulation of the CPS-I loci BPSL2793–BPSL2797 (wcbN-
wcbM-gmhA-wcbL-wcbK) when compared with its initial
isolate, with increases ranging from 2.7 to 6.1-fold (7 to
69). However, when compared with initial isolates from
CF6, CF8, CF9 and CF10, expression of BPSL2793–
BPSL2797 in the latter CF11 strain was in fact downregu-
lated (3.4 to 4.5-fold; 11 to 23). This observation was
confirmed as significant downregulation of these loci in the
initial CF11 strain (by between 6.1- and 10.1-fold; 69 to
1098) when compared with all other initial strains, rather
than significant upregulation of these CPS-I loci in the latter
CF11 strain.
Unlike CPS-I, expression of the CPS-II cluster (BPSS0417–
BPSS0429) is induced when grown in water, suggesting that
this polysaccharide plays a role in environmental survival
[29]. One locus involved in CPS-II biosynthesis, BPSS0425,
was downregulated (1.8-fold; 4) in CF6, and the entire
cluster was downregulated in CF9 (range 2.5- to 5.2-fold; 6
to 37). Conversely, BPSS0417 and BPSS0418 were upreg-
ulated in CF11 (~1.6-fold; 3). However, as with CPS-I,
both CF11 strains exhibited significant downregulation of
BPSS0417 and BPSS0418 when compared with initial strains
from CF6, CF8, CF9 and CF10 (2.0- and 3.1-fold; 4 to 9).
The genes encoding CPS-III (BPSS1825–BPSS1835) were
significantly downregulated in the latter isolates from CF6
(2.4- to 3.1-fold; 5 to 9) and CF9 (5.6- to 7.5-fold; 50 to
178). Finally, two genes within the CPS-IV cluster
(BPSL2769–BPSL2785) were downregulated in CF9
(BPSL2782 and BPSL2785; 1.8- to 2.8-fold; 3 to 7), but 11
of 17 loci from this cluster were upregulated in CF11 by 1.7-
to 5.9-fold (BPSL2769, BPSL2775–BPSL2784). However,
unlike CPS-I and CPS-II, this pattern of upregulation in
both CF11 isolates was maintained for CPS-IV loci
BPSL2769 and BPSL2775–BPSL2781 even when compared
with the initial CF6, CF8, CF9 and CF10 isolates (2.0- to
4.0-fold; 4 to 16).
DE of other virulence-associated loci
In addition to CPS-I and LPS, B. pseudomallei encodes for
several other virulence factors that enhance organism sur-
vival and replication upon infection or that subvert or dis-
arm host defences. These factors include adhesins, flagella,
fimbriae, pili, specialised secretion systems, actin motility
proteins, secreted factors and secondary metabolites [30].
Although virulence factors are often critically important
during the acute stages of infection, they can become disad-
vantageous for long-term survival, presumably due their
immunogenicity [12, 28]. Consistent with loss-of-virulence
as a pathoadaptive mechanism in chronic B. pseudomallei
infections, we have previously documented missense muta-
tions affecting the type 3 secretion system 3 (T3SS-3) gene
bsaW in CF6, and Burkholderia biofilm factor A-encoding
gene, bbfA, and fimbrial protein-encoding BPSL1628 in CF9
[14]. When examining RNA-seq profiles, other virulence
genes lacking genetic mutations were found to be signifi-
cantly downregulated in the latter CF isolates. These loci
included three type IV pilus 7 (TFP7) loci (pilR, pilG and
pilN; 1.7-fold; 3), the lysozyme inhibitor-encoding
BPSL1057 (3.4-fold; 11), Burkholderia lethal factor 1 (3.2-
fold; 10), four T3SS-3 loci (bsaS, bsaP, bsaO and bsaN),
and 15 flagellum loci in CF9 (mean 2.8-fold; 8), and a tri-
meric autotransporter adhesin (bpaC; BPSL1631) in CF11
(1.6-fold; 3). Of these, the four T3SS-3 loci are also miss-
ing in chronic P314 isolates. It is notable that no genetic
mutations were identified in these virulence factor loci in
the latter CF isolates, highlighting the advantage of using
transcriptomics to detect patterns of within-host pathogen
adaptation that are not observable with genomic data alone.
High-level trimethoprim/sulfamethoxazole (SXT)
resistance in B. pseudomallei involves bpeEF–oprC
upregulation
The combination antibiotic SXT, the drug of choice in the
eradication phase of melioidosis treatment [31], was admin-
istered to patients CF6, CF9 and CF11 during their
B. pseudomallei eradication attempts (Table 2). Acquired
resistance towards SXT emerged in the latter isolates from
CF6 and CF11, and in midpoint isolates from CF9 [14]. The
resistance-nodulation-division (RND) efflux pump, BpeEF–
OprC, is responsible for widespread trimethoprim resis-
tance in B. pseudomallei and has been implicated in SXT
resistance [32]. BpeEF–OprC (BPSS0292–BPSS0294)
expression is under the control of two LysR-type regulators,
BpeT (BPSS0290) and BpeS (BPSL0731). We, therefore,
expected to observe upregulation of bpeEF–oprC in CF
strains with elevated SXT minimum inhibitory concentra-
tions (MICs), consistent with defective bpeT or bpeS loci.
The latter isolate from CF6, which encodes a T314fs
mutation in bpeT and is highly resistant towards SXT
(MIC32 µgml 1), showed 5.2- to 6.8-fold upregulation of
bpeEF–oprC (38 to 111; Table 2). This isolate also har-
bours an R20fs mutation in ptr1 (BPSS0039; folM), which
encodes a pteridine reductase that is involved in SXT resis-
tance [32]; this frameshift truncates Ptr1 from 267 to 91 res-
idues. Both strains isolated from CF11 are also highly
resistant to SXT (MIC32 µgml 1) and encode the BpeS
missense variants V40I and R247L (K96243 annotation)
when compared with wild-type B. pseudomallei strains [14].
They also encode a three-residue in-frame insertion of R20-
A22 in Ptr1 [14, 32]. Because both CF11 strains are SXT
resistant, DE was determined by comparison with SXT-sen-
sitive isolates in our dataset. Using this approach, significant
upregulation was observed for BpeEF–OprC (5.3- to 6.9-
fold; 40 to 121; Table 2). DE was not observed for ptr1 or
other genes involved in the folate biosynthesis pathway in
either the CF6 or CF11 isolates (Table S1).
Ceftazidime (CAZ) resistance can occur by
upregulation of penA
CAZ is a third-generation cephalosporin antibiotic that is
the most commonly recommended therapy for the primary
phase of melioidosis treatment [33]. In addition to SXT, the
latter isolate from CF6 is highly resistant to CAZ
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(MIC256 µgml 1) [14]. High-level CAZ resistance is
often conferred by a C94Y substitution (C69Y using
Ambler’s [34] numbering scheme) in PenA b-lactamase
[35–37]. We have recently shown that the latter CF6 strain
also harbours a ~30 duplication of a 7.5 kb region that
encompasses penA; all 30 copies encode the C69Y variant of
this enzyme [14]. Consistent with this duplication event,
penA (BPSS0946) expression increased by 4.5-fold (22) in
the latter CF6 strain (Table 2). Six proximal genes
(BPSS0945; BPSS0948–BPSS0952) were also upregulated by
3.1- to 4.7-fold (9 to 26; Table S1). One of these,
BPSS0945, is a peptidase and a putative virulence factor that
may play a role in multinucleated giant cell formation [38].
A gene duplication event encompassing penA has also been
documented in the CF11 isolates. The initial strain showed
an elevated MIC towards CAZ (12 µgml 1), corresponding
with a ~10 duplication of a 36.7 kb region that includes
penA, whereas the latter strain had a 2 duplication of this
region and a wild-type CAZ MIC (2 µgml 1) [14]. As
expected, penA was downregulated by 2.1-fold (4) in the
latter isolate due to five times fewer copies of this gene
(Table 2). Downregulation of other genes within the 36.7 kb
locus ranged from 1.4- to 3.3-fold (3 to 10; Table S1).
Increased doxycycline MICs in CF11 are due to
amrAB–oprA upregulation and BPSL3085 mutation
Doxycycline was administered to CF11 in combination with
SXT as part of a final attempt to eradicate B. pseudomallei
[13, 33]. This lengthy administration led to a doxycycline
MIC of 4–8 µgml 1 in the CF11 isolates, both of which
were retrieved post-treatment [14].
The RND efflux pump, AmrAB–OprA (BPSL1802–
BPSL1804), efficiently effluxes aminoglycoside- and macro-
lide-class antibiotics [39]. We have recently shown that
synergistic mutations affecting both its regulator AmrR
(BPSL1805) and an S-adenosyl-L-methionine (SAM)-depen-
dent methyltransferase (BPSL3085) led to doxycycline resis-
tance in an Australian melioidosis case [40]. Consistent
with this earlier work, both CF11 strains encode a large
deletion in amrR (AmrRDV62-H223). This mutation results in
a 2.6- to 3.2-fold (6 to 9) upregulation of amrAB–oprA in
these isolates (Table 2). In addition, a previously undocu-
mented S130L mutation in BPSL3085 was observed in both
strains.
Decreased meropenem susceptibility is generally
conferred by amrAB–oprA upregulation
The latter isolate from CF11, a midpoint isolate from CF9
(MSHR5667), and both CF8 isolates possess elevated MICs
towards meropenem (3–4 µgml 1) [14]. Mutations in RND
efflux pump regulators, especially AmrR, are responsible for
this decreased susceptibility, and importantly, such cases are
associated with more refractory treatment and poorer
patient outcomes [41]. Alongside its elevated doxycycline
MIC, the AmrRDV62-H223 mutation in the latter CF11 isolate
also confers decreased meropenem susceptibility. The mid-
point CF9 isolate, MSHR5667, was not examined using
RNA-seq or quantitative PCR in our study, but we hypothe-
sise that its AmrRL132P mutation causes ~2–4-fold upregula-
tion of amrAB–oprA in a similar fashion to the CF11
isolates. Curiously, the CF8 isolates had no observed muta-
tions or DE loci involving efflux pumps when compared
with wild-type strains, and the basis for the elevated MIC in
these isolates remains elusive. Growing these isolates in the
presence of low-level meropenem to induce expression prior
to RNA-seq/quantitative PCR [42] may be required to
identify the transcriptional mechanism/s underpinning this
phenotype.
Evidence of convergent DE between early and
latter CF isolates
Finally, we performed a comparison of expression profiles
from all CF cases to identify a signal of convergent gene
expression (pathoadaptation) across early versus latter iso-
lates. To yield the most robust and relevant analysis, we
excluded the latter isolate from CF10 due to a lack of DE in
this strain, and the initial isolate from CF11, which was
retrieved >3 years after infection and had already undergone
substantial genetic and transcriptional modifications. Exclu-
sion of both strains was supported by a lack of convergent
signal when they were included in the analysis (data not
shown). Using these parameters, 17 genes were found to be
significantly upregulated, and 2 were significantly downre-
gulated (Table S3). Five (26%) loci encode for hypothetical
proteins with no known function, of which four were upreg-
ulated. Among the convergently upregulated genes with
known function was the RND efflux pump BpeEF–OprC
(4.8- to 6.1-fold; 28 to 69), the CydAB cytochrome bd qui-
nol oxidase (5.5- to 5.9-fold; 45 to 60), and the quorum
sensing hhqABCDEFG (BPSS0481–BPSS0487) operon (3.4-
to 4.1-fold; 11 to 17). The downregulated locus,
BPSS0351, encodes the MerR family transcriptional regula-
tor CueR (3.4-fold; 11).
DISCUSSION
The melioidosis pathogen, B. pseudomallei, is an uncom-
mon pathogen in CF, with fewer than 30 cases documented
worldwide to date. However, it is an important pathogen in
CF airways due to its ability to persist despite treatment and
its association with accelerating respiratory decline [13]. We
have recently performed comparative genomic analysis of
isogenic strains collected between 4 and 55months apart
from the airways of the patients in seven of these cases [14].
Here, we sought to further characterise these chronic cases
by examining the transcriptomes of five paired B. pseudo-
mallei isolates retrieved between 10 and 55months apart.
Although our sample numbers are modest, our study repre-
sents more than one-sixth of globally reported melioidosis
cases in CF to date.
Isolates were cultured in an artificial CF sputum medium
[18] to mimic their original in vivo environment. Under
these conditions, DE was detected in four of the five cases
and ranged from 32 to 792 genes, with the hypermutator
strain from CF9 contributing the greatest number of DE
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loci (Table S1). Interestingly, when compared with the
number of genetic changes occurring in each isolate pair,
the latter isolate from CF11 had a higher proportion of DE
loci to mutations (11.3) than CF9 (7.1), demonstrating that
hypermutation does not necessarily lead to a similarly high
number of transcriptional differences. The one case with
no DE, CF10, exhibited no genetic changes (i.e. SNPs,
small indels, copy-number variants or large deletions) and
had the shortest time between isolate collection at
10months [14]. All other cases encoded genetic differences
between pairs. The DE genes fell into several functional
categories (Table S1), reflecting the diversity and versatility
of pathoadaptive pathways in B. pseudomallei. Our RNA-
seq analysis revealed that many of the DE genes were
absent in the chronic P314 strain (range 9–97%), provid-
ing further evidence that these loci are not required for
long-term survival in the airways. Perhaps most striking
was the observation that nearly one-third (32%) of DE
genes lack a known function, highlighting the relative pau-
city of functional studies into this important yet under-
recognised pathogen.
B. pseudomallei has a ~7.3Mbp genome that is encoded on
two replicons; a ~4.1Mbp ‘housekeeping’ chromosome I
and a ~3.2Mbp ‘accessory’ chromosome II. The genome of
archetypal strain K96243 consists of 3460 and 2395 coding
sequences on chromosomes I and II, respectively [23].
There was a greater proportion of DE genes (between 52
and 97%) on chromosome II in all cases, despite its smaller
size and fewer coding sequences. We have previously shown
that a greater proportion of mutational events affect chro-
mosome II of B. pseudomallei in a long-term chronic-car-
riage isolate from P314 [28]. The skew towards DE loci on
chromosome II in chronic B. pseudomallei isolates points
towards a lesser role for chromosome II loci in bacterial sur-
vival and persistence within the human host, which is
reflected by the greater degree of reductive evolution affect-
ing this replicon [14, 28]. In their study of the transcrip-
tional landscape of B. pseudomallei, Ooi and co-workers
found that only ~28% of chromosome II genes were
expressed under a single condition, compared with ~72% of
chromosome I genes [43]. Taken together, these results sup-
port the accessory role of the chromosome II replicon in
B. pseudomallei.
Attenuation of immunogenic surface antigens and other vir-
ulence factors are hallmarks of chronically persistent infec-
tions across many pathogenic bacterial species, including
B. pseudomallei [14, 28]. Encoded by the 34.5 kb wcb operon
BPSL2786–BPSL2810 [44, 45], the B. pseudomallei CPS-I is
a potent virulence determinant that imparts high-level
serum resistance and facilitates phagocytic evasion [45].
This capsule is also intact in the equine-adapted B. pseudo-
mallei clone, Burkholderia mallei, where it and has been
shown to be essential for its virulence [46, 47]. Our prior
genomic analysis identified only a single CF pair with
mutated CPS-I in CF11. This frameshift mutation in wcbA
results in a truncated protein [14] that likely causes reduced,
although not abolished, CPS-I production [48]. The DE
analysis provides further evidence of CPS-I inactivation in
the CF pairs, with downregulation of all but one of the CPS-
I loci in the latter CF9 isolate, and downregulation of wcbN-
wcbM-gmhA-wcbL-wcbK in both CF11 isolates. Although
CPS-III is not required for virulence, it is noteworthy that
this locus was also downregulated in CF9 and CF11, as it
has been previously shown that CPS-III expression is tied to
that of CPS-I genes [43].
Like CPS-I, the B. pseudomallei LPS is required for capsule
biosynthesis, virulence and serum resistance [49]. Its immu-
nogenic outer-membrane component is readily recognised
by the host innate immune system [50], which makes LPS a
target for inactivation in chronic bacterial infections. We
have previously uncovered missense mutations in the LPS
wzt and rmlA loci of CF6, and a missense mutation affecting
BPSL1119 in CF11 [14]. DE analysis identified additional
evidence for reduced or abolished LPS production in a third
CF case, CF9, due to the significant downregulation of
wbiD, wbiE and BPSS1683–BPSS1685. Prior work has sug-
gested that CPS-I and LPS may be disadvantageous for
B. pseudomallei persistence due to their virulence potential
and immunogenicity [28]. By examining both genomic and
transcriptomic modifications over time, it is now clear that
these capsule clusters, in their wild-type form, pose a major
issue for successful long-term B. pseudomallei persistence in
the CF lung, with the bacterium either mutating or downre-
gulating key genes in CPS-I and LPS pathways. We also
observed genetic mutation or transcriptional downregula-
tion of other virulence genes in latter CF strains including
TFP7 loci, Burkholderia lethal factor 1, T3SS-3 loci and fla-
gellum loci, suggesting that these loci are similarly detri-
mental to long-term B. pseudomallei survival in the human
host. Importantly, the RNA-seq data identified additional
cases of surface antigen and virulence factor abrogation that
were not observable with only genomic data. This finding
underscores the importance of using both genomic and
transcriptomic approaches to identify the functional conse-
quences of within-host evolution of chronic bacterial
infections.
SXT is used during the eradication phase of melioidosis
treatment and is recommended for post-exposure prophy-
laxis [51]. We have previously shown that the latter isolate
from CF6, and both isolates from CF11, had developed
high-level (32 µgml 1) SXT resistance over the course of
treatment. These elevated MICs were proposed to be due to
mutations within BpeEF–OprC efflux pump regulators
(BpeT T314fs in CF6, and BpeS V40I and R247L in CF11)
alongside mutations affecting the R20 residue of Ptr1/FolM
(R20fs in CF6; R20-A22 duplication in CF11) [14]. Here, we
have demonstrated that the efflux pump regulatory muta-
tions cause a dramatic upregulation of bpeEF–oprC in these
strains of between 5.2- and 6.9-fold (38 to 121), mirroring
expression levels in bpeS and bpeT laboratory-generated
mutants with high-level SXT resistance [32]. Our results
confirm those of Podnecky and colleagues [32] showing
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that upregulation of bpeEF–oprC via BpeS or BpeT dysregu-
lation, together with Ptr1/FolM alteration, leads to a signifi-
cant increase in SXT MICs that would render this antibiotic
ineffective in vivo. RNA-seq is, thus, a useful tool for observ-
ing the functional consequences of regulatory mutations
that control RND efflux pump expression.
In addition to SXT resistance, the initial isolate from
CF11 (12 µgml 1) and the latter isolate from CF6
(256 µgml 1) are resistant to CAZ. Our prior genomic
study showed that CAZ resistance in the initial CF11
strain was due to a 10 duplication of a 36.7 kb region
encompassing the b-lactamase gene, penA, the first time
that gene duplication has been shown to confer CAZ
resistance in B. pseudomallei. In contrast, a 2 duplica-
tion of this region in the latter strain did not raise the
CAZ MIC above wild-type levels [14]. Similarly, the latter
strain from CF6 exhibits a 30 duplication of a 7.5 kb
region encompassing penA; however, all 30 copies encode
a C69Y missense mutation, which by itself causes high-
level (256 µgml 1) CAZ MICs [35]. RNA-seq confirmed
the penA duplications, with the 30 variant from CF6
observed as 4.5-fold (22) upregulation. Similarly, a 2.1-
fold (4) downregulation of penA in the latter strain
from CF11 was linked to a 5 greater copy number in
the early strain [14]. Thus, RNA-seq provides excellent
correlation with gene copy number variation determined
from whole-genome sequence coverage data. Taken
together, the combined genetic and transcriptional
changes affecting antibiotic resistance genes in the CF air-
ways-adapted B. pseudomallei strains illustrates both the
intractability of eradicating chronic bacterial infections
and the unintended consequences of prolonged antibiotic
use in CF treatment.
Although determining within-host transcriptional differen-
ces in longitudinal isolates yields valuable insights into the
infection dynamics within individual patients, identifying
convergent transcriptional changes provides a potential
means to predict pathogen behaviour and evolution across
multiple CF cases in a relatively straightforward manner.
Such predictability could conceivably be exploited to
improve the diagnosis or treatment of intractable CF infec-
tions, or ideally, to prevent them from progressing in the
first place. Therefore, a major objective of this study was to
identify evidence of convergence in B. pseudomallei gene
expression during its transition to a chronic infection.
Despite the small number of CF melioidosis patients avail-
able for this study, a signal of convergent pathoadaptation
was identified between the initial and latter isolates, with 19
significantly DE loci identified, 17 of which were upreg-
ulated (Table S3). This convergence is noteworthy given the
large size of the B. pseudomallei genome and the many
redundant pathways that could lead to similar adaptive phe-
notypes, a phenomenon that is well-recognised in P. aerugi-
nosa [52]. One advantage of identifying convergence using
transcriptomics rather than genomic data is that it can
reveal the transcriptional consequence of multiple genetic
mutations; for example, we have observed that multiple mis-
sense mutations in the RND efflux pump regulator AmrR
lead to the same transcriptional outcome of amrAB–oprA
upregulation [41]. As such, RNA-seq data can simplify the
identification of convergently expressed loci that can be dys-
regulated by multiple genetic variants.
The development of antibiotic resistance is a recurring
theme in P. aeruginosa isolated from the CF airways [12],
and we have recently shown that the same adaptive phe-
nomenon can be observed in the genome of B. pseudomallei
in response to prolonged, high-dose antibiotic therapy [14].
It was, therefore, not surprising to identify the convergent
upregulation of bpeEF–oprC (4.8- to 6.1-fold; 28 to 69),
which was significantly upregulated in two of the four
patients with DE (CF6 and CF11), and which led to SXT
resistance as discussed above. The second convergently
upregulated locus was the cydAB operon (BPSL0501 and
BPSL0502), which encodes cytochrome bd quinol oxidase
(5.5- to 5.9-fold; 45 to 60); this locus was significantly dif-
ferentially expressed in CF6 and CF9. CydAB is an aerobic
terminal oxidase that oxidizes ubiquinol-8 and reduces oxy-
gen to water under oxygen-limiting conditions. This
enzyme is better able to scavenge oxygen under microaero-
bic conditions compared with cytochrome o oxidase, which
otherwise predominates as the terminal respiratory enzyme
in electron transport-associated energy production [53].
Voggu and colleagues demonstrated that non-pathogenic
Staphylococcus species were better able to resist P. aerugi-
nosa antagonism compared with Staphylococcus aureus due
to the insensitivity of the non-pathogenic staphylococci
cytochrome bd quinol oxidases to the presence of the small
respiratory inhibitors hydrogen cyanide and pyocyanin,
which are commonly secreted by P. aeruginosa in the CF
lung [54]. Thus, it is feasible that the convergent upregula-
tion of cydAB loci represents a defence mechanism
employed by B. pseudomallei to counteract the toxic effects
of small respiratory inhibitors produced by P. aeruginosa in
the CF lung. In support of this hypothesis, P. aeruginosa
was co-isolated in all five CF cases examined in this study
[14]. Alternatively, cydAB upregulation may simply repre-
sent a physiological response to the oxygen-limited environ-
ment of the CF airways, as its expression is known to be
induced in B. pseudomallei in hypoxic conditions [55].
Under hypoxia, many pathogens including B. pseudomallei
become less susceptible to conventional antibiotics, which
are typically effective under aerobic conditions, but more
susceptible to antibiotics that target anaerobic infections.
One example is the nitroimidazole class of antibiotics [55],
which reduce their nitro group only under hypoxic condi-
tions, causing DNA strand breakage and bacterial cell death
[56]. This phenomenon may explain the difficulties with
chronic B. pseudomallei eradication using conventional
antibiotics like CAZ and SXT, and raises the exciting but
not-yet-tested possibility that nitroimidazoles may be a
highly effective therapeutic option for chronic, hypoxia-
adapted B. pseudomallei infections such as those adapted to
the CF airways.
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A third convergently upregulated locus, the quorum sensing
operon hhqABCDEFG (3.4- to 4.1-fold; 11 to 17), is
homologous to the B. cepacia complex hmqABCDEFG
operon [57]. This operon synthesises a class of compounds
known as 4-hydroxy-3-methyl-2-alkylquinolines (HMAQs),
the methylated counterparts of 2-alkyl-4(1H)-quinolones
(AHQs; also known as HAQs). AHQs were first recognised
in P. aeruginosa and are produced by the signalling system
pqsABCDE [58]. This cluster produces over 50 different
AHQs, and these compounds exhibit diverse biological
activities that enable cell-to-cell communication within and
between bacterial species and the regulation of various func-
tions including secondary metabolism, virulence, antibacte-
rial activity and biofilm formation [58]. In contrast, little is
currently known about the role of HMAQs and AHQs in
Burkholderia spp. [57]. The AHQ precursor molecule 2-
heptyl-4(1H)-quinolone (HHQ) that is produced by P. aer-
uginosa actively suppresses the host innate immune
response [59], a role that could be shared by B. pseudomallei
HHQ. A second possibility is that these compounds impart
a competitive advantage in the CF lung environment as
HMAQs produced by B. cepacia exhibit antifungal activity
[60], so it is feasible that the hmqABCDEFG operon of
B. pseudomallei produces similarly potent compounds that
can inhibit fungal species from establishing residence in the
CF lung. The convergent upregulation of hhqA–hhqG in the
B. pseudomallei CF isolates points to a putative role for
AHQ-based compounds in B. pseudomallei signalling,
immune evasion or competition in the CF lung. More work
is needed to elucidate the myriad functions of AHQ com-
pounds in B. pseudomallei, and particularly their role in
promoting bacterial persistence in the CF airways.
Of the two convergently downregulated loci, only one,
BPSS0351, has an assigned function, although little is known
about the role of this gene and its product in B. pseudomal-
lei. This gene encodes CueR (3.4-fold; 11), a MerR family
copper response regulator that is highly sensitive to the
presence of copper (Cu) and which regulates the tran-
scription of genes that protect against toxic metal ion con-
centrations [61, 62]. Cu has a long history as an effective
antimicrobial agent due its ability to generate reactive oxy-
gen species, with Cu accumulation in the mammalian host
purported to act as an innate immune defence mechanism
to restrict pathogen growth [63]. Thus, downregulation of
cueR in the latter CF isolates may represent a mechanism
for mitigating Cu toxicity in the host, similarly to Escheric-
hia coli [62]. However, there are contradictory reports as to
whether Cu levels are elevated in CF sputa [64, 65], and the
artificial sputum growth medium does not appear to con-
tain elevated Cu levels [18]. CueR regulates the Cu/silver
ATPase CopA and the multicopper oxidase CueO enzymes
in E. coli, which correspond to BPSS0224 and BPSL0897 in
B. pseudomallei K96243, respectively; however, neither of
these genes showed DE in any of the patient pairs. The
absence of concomitant increased expression of cueO, which
converts periplasmic Cu+ to less toxic Cu2+ in vivo [38],
suggests that other enigmatic pressures are responsible for
decreasing cueR expression in latter CF isolates. The biologi-
cal role of these other factors requires further exploration.
We recognise that there are limitations to our study. Growth
conditions are known to be an important consideration for
mRNA-based investigations due to the alteration of the
transcriptome when isolates are grown under different envi-
ronments or media components [66]. Although our in vitro
conditions do not completely mimic the conditions seen in
the CF lung, the artificial sputum medium is designed to
reflect the nutrient conditions of this environment [18], and
our shaking parameters provided a robust way of measuring
cellular growth over time while avoiding non-uniform cellu-
lar growth, which ensured harvest of B. pseudomallei cul-
tures at the same growth phase (Fig. S1). Additionally, the
use of isogenic strain pairs with genomic data [14] enabled
us to comprehensively assess the effects of transcriptional
adaptation to the CF lung compared with their underlying
genetic variants. Our conditions provided transcriptomic
data that were consistent with expected expression differen-
ces based on genome-wide alterations. Other studies have
used artificial sputum media and additional mechanical
methods to mimic the CF lung conditions. A rotating wall
vessel has been developed to simulate the low fluid shear
conditions encountered in CF mucus due to pathological
effects of CFTR dysfunction on mucociliary clearance [67],
with CF-derived P. aeruginosa isolates demonstrating tran-
scriptional differences depending on shear conditions [19].
The culturing methods for bacterial RNA-seq are a critical
consideration in experimental design as they can affect tran-
scriptomic profiles, and the impact of conditions should be
considered when comparing transcriptional differences
between studies. Another shortcoming is that we only
examined five patient pairs due to the relative paucity of
melioidosis CF cases worldwide, and only two isolates from
each patient due to limited bacterial colony selection and
storage at the time of sputum collection and processing.
Deeper sampling efforts across a greater number of melioi-
dosis CF patients would be needed to provide greater confi-
dence in our convergent adaptation findings and would
allow a more thorough understanding of B. pseudomallei
population dynamics and diversity to be attained. Neverthe-
less, the findings from our study provide important new
insights into B. pseudomallei evolution in the CF airways,
with many, although not complete, parallels with the com-
mon CF pathogens, P. aeruginosa and B. cepacia complex
species.
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